Wyeth threatens suit against Teva
- Share via
From Times Wire Services
A patent dispute over the heartburn drug Protonix escalated when Wyeth said it would sue to recover lost profit from sales of Teva Pharmaceutical Industries’ generic version. The companies are discussing a possible settlement.
Teva has a 180-day period of market exclusivity for being the first company to file for a generic version of Protonix. Teva does not dispute that it infringed Wyeth’s patent but argues that the patent itself is not valid.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
